Search

Arcutis Biotherapeutics Inc

Fechado

SetorSaúde

31.96 1.72

Visão Geral

Variação de preço das ações

24h

Atual

Mín

30.95

Máximo

32.01

Indicadores-chave

By Trading Economics

Rendimento

26M

15M

Vendas

24M

130M

P/E

Médio do Setor

144.591

50.373

EPS

0.11

Margem de lucro

11.558

Funcionários

354

EBITDA

23M

17M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+26.66% upside

Dividendos

By Acuity

Próximos Ganhos

4 de nov. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

754M

4B

Abertura anterior

30.24

Fecho anterior

31.96

Arcutis Biotherapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de out. de 2026, 21:21 UTC

Arcutis Biotherapeutics, Inc. is trading modestly higher in after-market hours, reflecting strength in the Biotechnology sub-sector and continuing a strong performance trend.

27 de out. de 2026, 19:26 UTC

Arcutis Biotherapeutics, Inc. shares fell slightly, retracing some gains but remaining above its 20-day moving average and near the upper end of its one-month range.

26 de out. de 2026, 20:13 UTC

Arcutis Biotherapeutics Inc shares are trading lower in after-market hours, continuing a downward trend that began since Monday's close.

23 de out. de 2026, 20:01 UTC

Arcutis Biotherapeutics Inc shares are declining sharply, with a cumulative return significantly lower since Thursday's close, reflecting weaker performance compared to recent trends.

22 de out. de 2026, 20:07 UTC

Social Media

Arcutis Biotherapeutics Inc shares are modestly higher, approaching their 52-week high, amid strong sales of ZORYVE and anticipation for Q3 earnings.

21 de out. de 2026, 19:36 UTC

Arcutis Biotherapeutics Inc shares fell sharply, retracing from earlier gains.

20 de out. de 2026, 22:26 UTC

Arcutis Biotherapeutics Inc shares are trading modestly lower in after-market hours, having retraced from a brief peak earlier in the session.

19 de out. de 2026, 22:01 UTC

Arcutis Biotherapeutics Inc is trading higher in after-market hours, following a strong position after Monday's close, despite a decline in the NAHB Housing Market Index.

16 de out. de 2026, 20:13 UTC

Arcutis Biotherapeutics Inc shares declined during after-market hours, aligning with broader market trends amid mixed economic data on inflation and fiscal management.

15 de out. de 2026, 20:01 UTC

News

Cantor Fitzgerald initiated coverage on Arcutis Biotherapeutics with an Overweight rating and a price target of $48, contributing to notable trading volume.

14 de out. de 2026, 22:52 UTC

Arcutis Biotherapeutics Inc shares are moving modestly lower in after-market hours, reflecting a broader market decline following a consumer inflation report.

13 de out. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc shares fell modestly, reaching a low in the morning before recovering but ultimately settling near the lower end of its range.

12 de out. de 2026, 20:06 UTC

Event

Arcutis Biotherapeutics presented data on its ZORYVE® portfolio at two dermatology conferences, leading to a decline in shares during Monday's session.

9 de out. de 2026, 20:01 UTC

Event
Macro Event
News

Arcutis Biotherapeutics presents positive ZORYVE data at EADV Congress, showing 34.4% of infants and 66.4% of patients achieving clear skin in trials.

8 de out. de 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are gaining.

6 de out. de 2026, 20:00 UTC

Event

Shares of Arcutis Biotherapeutics Inc fell despite the company's ZORYVE® cream winning the 2026 "Best Prescription Skin Solution" Award from Marie Claire magazine.

1 de out. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc shares fell sharply, continuing a trend of three consecutive lower daily closes amid challenges in the biotechnology sector.

29 de set. de 2026, 20:07 UTC

News

Arcutis Biotherapeutics launched the "Skin to Believe In" campaign with Simone Biles, as shares fell lower after an initial gain at market open.

28 de set. de 2026, 19:15 UTC

Arcutis Biotherapeutics Inc is trading higher, reaching a peak return of nearly 2% and remaining significantly above its 20-day moving average.

25 de set. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc is advancing during the session, building on gains since Thursday, trading above its 20-day moving average and near its one-month high.

24 de set. de 2026, 20:07 UTC

Arcutis Biotherapeutics Inc's shares fell, continuing a downward trend since Wednesday, despite earlier fluctuations that saw a pullback from a session high.

23 de set. de 2026, 20:01 UTC

Arcutis Biotherapeutics Inc shares fell sharply, breaking a recent trend of higher daily closes, diverging from the upward movement observed in prior sessions.

22 de set. de 2026, 20:01 UTC

Arcutis Biotherapeutics Inc is advancing sharply, continuing its upward trend since Monday's close, despite an earlier pullback from a session high.

21 de set. de 2026, 23:15 UTC

Arcutis Biotherapeutics Inc declined in after-market trading on Monday, remaining below its earlier low but above its 20-day moving average.

18 de set. de 2026, 22:11 UTC

Arcutis Biotherapeutics Inc is trading modestly lower in after-market hours, continuing a cumulative decline since Friday's close despite a brief uptick earlier.

17 de set. de 2026, 23:16 UTC

Arcutis Biotherapeutics Inc saw a modest decline during after-market hours, despite remaining above its 20-day moving average and near the upper end of its one-month range.

16 de set. de 2026, 23:06 UTC

Arcutis Biotherapeutics Inc is gaining in after-market trading, recovering from earlier declines to peak above the previous close, currently 7.38% above its 20-day moving average.

15 de set. de 2026, 20:07 UTC

Arcutis Biotherapeutics shares are lower today amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index.

14 de set. de 2026, 20:02 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing, having rebounded from an early session low amid broader market concerns over rising crude oil prices.

11 de set. de 2026, 19:46 UTC

Arcutis Biotherapeutics is gaining today, reaching earlier highs amid broader market reactions to Consumer Price Index data and interest rate speculation.

Comparação entre Pares

Variação de preço

Arcutis Biotherapeutics Inc Previsão

Preço-alvo

By TipRanks

26.66% parte superior

Previsão para 12 meses

Média 39.833 USD  26.66%

Máximo 48 USD

Mínimo 34 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Arcutis Biotherapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat